No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GPCR240719P45000
- 6.10
- +1.35+28.42%
15min DelayClose Jul 18 15:59 ET
6.10High6.10Low
6.10Open4.75Pre Close1 Volume393 Open Interest45.00Strike Price610.00Turnover237.83%IV-2.64%PremiumJul 19, 2024Expiry Date7.10Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8761Delta0.0386Gamma5.12Leverage Ratio-0.2981Theta-0.0013Rho-4.49Eff Leverage0.0046Vega
Intraday
- 5D
- Daily
News
Eli Lilly's Stock Plunges as Investors Eye Obesity-drug Competition
By Eleanor Laise 'Vast' weight-loss drug pipeline keeps Lilly in a strong position as field gets crowded, analysts say Eli Lilly & Co.'s stock was on pace for its worst day in about three years
Express News | Shares of Weight Loss Stocks Are Trading Lower, Possibly on Continued Weakness Following Recent Weight Loss Data From Roche, Which Could Cause Competition Concerns for Companies in the Space
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) fell sharply during Wednesday's session after the company announced that its Singapore-incorporated, sole operating subsidiary has filed for
Express News | Structure Therapeutics Shares Are Trading Lower Following Weight Loss Data From Competitor Roche
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics Inc (NASDAQ:VKTX), and Structure Therapeutics Inc (NASDAQ:GPCR) stocks are trading lower on Wednesday.What happened?
Roche Obesity-pill Trial Results Weigh on Shares of Eli Lilly, Novo Nordisk
By Eleanor Laise Selloff of weight-loss drug developers' stocks is overdone, some analysts say Shares of weight-loss drug developers including Eli Lilly & Co., Novo Nordisk and Structure
Comments
$ROCHE HOLDING AG(RHHBY.US$
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co(LLY.US$ $Novo-Nordisk A/S(NVO.US$ $Structure Therapeutics(GPCR.US$ $Viking Therapeutics(VKTX.US$ $Lipocine(LPCN.US$
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co(LLY.US$ $Novo-Nordisk A/S(NVO.US$ $Structure Therapeutics(GPCR.US$ $Viking Therapeutics(VKTX.US$ $Lipocine(LPCN.US$
5
Why do you think $Pfizer(PFE.US$ decided to progress with Danuglipron? (![]()
Can't give up this huge market?
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
+1
5
It seems that they will be going for acquisition of easy to manufacture weight loss pills $Structure Therapeutics(GPCR.US$
News offering dropped🤢 ❗️❗️❗️**FOR IMMEDIATE RELEASE** Globe wire newsletter June 3,2024 2:57 pm est
Therapeutics Inc, a leading biopharmaceutical company, public offer at $31.90 per share USD for the acquisition of 17 million shares. The offer is subject to closing on June 7, 2024. This move reflects the company's commitment to expanding its market presence and fostering financial growth. Investors and stakeholders are urged to capitalize on this lucrative opportunity. Therapeutics Inc antici...
Therapeutics Inc, a leading biopharmaceutical company, public offer at $31.90 per share USD for the acquisition of 17 million shares. The offer is subject to closing on June 7, 2024. This move reflects the company's commitment to expanding its market presence and fostering financial growth. Investors and stakeholders are urged to capitalize on this lucrative opportunity. Therapeutics Inc antici...
1
Read more